| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025
Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027
Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET
LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease (TED). The Company will host a virtual investor event today, Monday, January 6, 2025 at 4:30 PM ET. To register, click here.
Posted In: SLRN
